KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2016 - 2025)

Ionis Pharmaceuticals has reported Total Non-Current Liabilities over the past 13 years, most recently at $2.4 billion for Q3 2025.

  • Quarterly results put Total Non-Current Liabilities at $2.4 billion for Q3 2025, up 26.9% from a year ago — trailing twelve months through Sep 2025 was $2.4 billion (up 26.9% YoY), and the annual figure for FY2024 was $2.4 billion, up 13.1%.
  • Total Non-Current Liabilities for Q3 2025 was $2.4 billion at Ionis Pharmaceuticals, up from $2.3 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for IONS hit a ceiling of $2.6 billion in Q3 2023 and a floor of $1.8 billion in Q4 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $2.1 billion (2023), compared with a mean of $2.1 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: fell 26.82% in 2024 and later increased 26.9% in 2025.
  • Ionis Pharmaceuticals' Total Non-Current Liabilities stood at $1.8 billion in 2021, then grew by 6.98% to $2.0 billion in 2022, then rose by 6.56% to $2.1 billion in 2023, then rose by 13.1% to $2.4 billion in 2024, then grew by 0.97% to $2.4 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $2.4 billion (Q3 2025), $2.3 billion (Q2 2025), and $2.3 billion (Q1 2025) per Business Quant data.